
As a former Dean and appointed Distinguished University Professor and Endowed Department Chair Dr. David Edward Marcinko MBA was a NYSE broker and investment banker for a decade who was respected for his unique perspectives, balanced contrarian thinking and measured judgment to influence key decision makers in strategic education, health economics, finance, investing and public policy management.
Dr. Marcinko is originally from Loyola University MD, Temple University in Philadelphia and the Milton S. Hershey Medical Center in PA; as well as Oglethorpe University and Emory University in Georgia, the Atlanta Hospital & Medical Center; Kellogg-Keller Graduate School of Business and Management in Chicago, and the Aachen City University Hospital, Koln-Germany. He became one of the most innovative global thought leaders in medical business entrepreneurship today by leveraging and adding value with strategies to grow revenues and EBITDA while reducing non-essential expenditures and improving dated operational in-efficiencies.
Professor David Marcinko was a board certified physician, surgical fellow, hospital medical staff Vice President, public and population health advocate, and Chief Executive & Education Officer with more than 425 published papers; 5,150 op-ed pieces and over 135+ domestic / international presentations to his credit; including the top ten [10] biggest drug and pharmaceutical companies and financial services firms in the nation. He is also a best-selling Amazon author with 30 published academic text books in four languages [National Institute of Health, Library of Congress and Library of Medicine].
Dr. David E. Marcinko is past Editor-in-Chief of the prestigious “Journal of Health Care Finance”, and a former Certified Financial Planner® who was named “Health Economist of the Year” in 2010. He is a Federal and State court approved expert witness featured in hundreds of peer reviewed medical, business, economics trade journals and publications [AMA, ADA, APMA, AAOS, Physicians Practice, Investment Advisor, Physician’s Money Digest and MD News] etc.
Later, Dr. Marcinko was a vital recruited BOD member of several innovative companies like Physicians Nexus, First Global Financial Advisors and the Physician Services Group Inc; as well as mentor and coach for Deloitte-Touche and other start-up firms in Silicon Valley, CA.
As a state licensed life, P&C and health insurance agent, SEC registered representative Marcinko was Founding Dean of the fiduciary and niche focused on-line CERTIFIED MEDICAL PLANNER® chartered designation education program; as well as Chief Editor of the 3 print format HEALTH DICTIONARY SERIES® and online Wiki Project.
Dr. David E. Marcinko’s professional memberships included: ASHE, AHIMA, ACHE, ACME, ACPE, MGMA, FMMA and HIMSS. He was a MSFT Beta tester, Google Scholar, “H” Index favorite and one of LinkedIn’s “Top Cited Voices”.
Marcinko is “ex-officio” and R&D Scholar-on-Sabbatical for iMBA, Inc. who was recently appointed to the MedBlob® [military encrypted medical data warehouse and health information exchange] Advisory Board.


A New Drug Pricing Report
Did you know that according to Delta Marketing Dynamics, the nation’s pharmaceutical companies increased wholesale prices for the 50 top-selling branded drugs by an average of 7.82 percent in 2007? And, similar increases of 6.73 percent and 6.22 percent were noted in the previous two years that were almost double the overall U.S. economy’s 4.1 percent annual inflation rate.
Some individual drugs even had double-digit price increases over three years. For example:
• GlaxoSmithKline PLC raised the price of antidepressant Wellbutrin XL by 44.5 % from 2005-07;
• Sanofi-Aventis SA raised the price of sleep drug Ambien 70.1 percent;
• Shire PLC increased the price of attention-deficit disorder medication, Adderall XR, by 33.5%;
• Cholesterol fighting Lipitor-the world’s top selling drug that made $13 billion in 2007 for Pfizer Inc-rose 16 %.
The report was published in the Wall Street Journal.
Jake
LikeLike
Pharma Companies Spent $148,047,760 on Lobbying in 2015
The LA Times recently released an article on healthcare industry political lobbying. Here are some key findings from the report:
• Pharmaceutical manufacturing spent $148,047,760 on lobbying in 2015.
• Hospitals and nursing homes spent $93,592,884 on lobbying in 2015.
• Health professionals (including physician groups) spent $89,928,202.
• Health services/insurers/HMOs spent $74,356,196 on lobbying in 2015.
• In 2016 pharmaceutical companies contributed over $17 million to campaigns.
• The top recipient of industry money was Paul Ryan who received $230,000+
Source: LA Times, November 15, 2016
LikeLike
Janssen Spent $7 Billion on Research and Development in 2016
Janssen recently released a price transparency report for 2016. Here are some key findings from the report:
• Janssen spent $7 billion on research and development in 2016.
• The average list price change of Janssen pharmaceuticals was 8.5%.
• The average net price change of Janssen pharmaceutical products was 3.5%.
• Janssen offered $11 billion dollars in total rebates and discounts in 2016.
• 870,000 commercially insured patients used the Janssen CarePath Savings Program.
• Janssen spent $4.5 billion on global pharmaceutical marketing and sales.
Source: Janssen, February 27, 2017
Shuster
LikeLike